Skip to content
Search

Latest Stories

Boots Pharmacists’ Association merges with PDA Union

Boots Pharmacists’ Association ceases as a separate organisation after 51 years
The entrance to a Boots pharmacy and beauty shop in Edinburgh Airport. (gettyimages)

The merger marks the end of the Boots Pharmacists’ Association (BPA)’s 51-year history as an independent organisation  

After over half a century of operation, the Boots Pharmacists’ Association (BPA) will cease as a separate organisation and merge into the PDA Union, effective 1 January 2025.

This landmark decision follows extensive discussions between the two organisations, approval from the trade union regulator, and strong support from BPA members, with 96 per cent voting in favour of the merger via postal ballot.


The merger means that existing BPA members will automatically transfer to the PDA Union, joining thousands of other PDA members employed at Boots. Transferred members will receive regular updates from the PDA.

Founded in 1973, the BPA was originally formed as the Joint Boots Pharmacists Association (JBPA), uniting local groups such as Strathclyde Boots Pharmacists and Birmingham and District Boots Pharmacists.

It was established to present a united voice against the proposal from the then European Common Market that individual pharmacists should own pharmacy equipment and medicines in their pharmacies. Recognised as a trade union in 1979, the JBPA rebranded as the Boots Pharmacists’ Association in 1997 to reflect its status as a membership organisation.

In 2012, the BPA achieved formal recognition from Boots. However, in 2018, pharmacists at Boots voted to derecognise the BPA, subsequently recognising the PDA Union in 2019.

Despite this, the BPA and PDA Union maintained a collaborative and professional relationship, meeting periodically to discuss matters of concern to pharmacists.

As the BPA marked its 50th anniversary in 2023, its leadership acknowledged that continuing as a separate organisation was not sustainable long-term.

Following extensive talks, the BPA and PDA Union announced in October that they had reached an agreement on the terms of a merger. The proposal was formally approved by the trade union regulator before being presented to BPA members for a vote via ballot.

Khuram Ahmad, chairman of the BPA, stated: “BPA Executive Committees have led our association for over half a century and have now secured a future for the membership which they have confirmed that they want. We will ensure a smooth transition to the PDA Union at year end.”

Mark Pitt, general secretary of PDA Union, expressed enthusiasm about the merger, highlighting that the PDA is "the only trade union exclusively for pharmacists."

"We look forward to welcoming hundreds more into PDA membership through this merger," he added.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less